Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Venetoclax is effective in CLL that relapses after idelalisib,

Coutre S et al. Blood. 2018;131(15):1704-11

Publish date:

Key clinical point: Venetoclax had efficacy against relapsed/refractory chronic lymphocytic leukemia (CLL) following idelalisib therapy.

Major finding: The overall response rate was 67%, including two complete responses (CRs) and one CR with incomplete bone marrow recovery.

Study details: Cohort of 36 patients with relapsed/refractory CLL previously treated with idelalisib.

Disclosures: Genentech and AbbVie funded the study. Dr. Coutre is an advisory board member for both companies and others, and receives institutional funding from AbbVie and others. Multiple coauthors disclosed financial relationships with AbbVie, Genentech, or both, as well as other companies.

Source: Coutre S et al. Blood. 2018;131(15):1704-11.

Read the article.

Citation:

Coutre S et al. Blood. 2018;131(15):1704-11.

This Week's Must Reads